Here’s Why You Should Retain Allscripts (MDRX) Stock For Now

Allscripts Healthcare Solutions, Inc. MDRX is well-poised for growth in the coming quarters, backed by its strategic alliances over the past few months. A robust second-quarter 2021 performance, along with various innovation milestones, is expected to contribute further. However, healthcare regulatory changes and foreign exchange concerns persist.

Over the past year, this Zacks Rank #3 (Hold) stock has surged 35.3% against 29.2% fall of the industry it belongs to. The S&P 500 composite rose 31.7% in the said time frame.

The renowned IT solutions and services provider has a market capitalization of $1.78 billion. The company projects 9.7% growth for the next five years and expects to maintain its strong performance. It has delivered an earnings surprise of 24.35% for the past four quarters, on average.

 

Patient Support / Hub Services Continue to Evolve

The goal of producing meaningful data is driving industry progress. The business of providing outsourced patient support and hub services is growing...

Read More

A Conversation with Mark Hansan, CareMetx

CareMetx was founded in 2011 by two longtime industry executives, Bob Dresing and Mark Hansan, who started in the patient support field in the 1980s....

Read More

Value-based agreements could disrupt how we pay for new therapies

On Tuesday, the Senate Finance Committee will hold its second hearing in a series on drug pricing. Led by chairman Senator Chuck Grassley (R-Iowa)...

Read More